Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Edap Tms SA (NASDAQ:EDAP)

3.74
Delayed Data
As of Jul 31
 +0.09 / +2.47%
Today’s Change
1.15
Today|||52-Week Range
4.09
+60.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$88.6M

Company Description

EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Contact Information

EDAP TMS SA
Parc d'Activités la Poudrette-Lamart
Vaulx-en-Velin Rhone-alpes 69120
P:(347) 215-3150
Investor Relations:
(347) 826-4046

Employees

Shareholders

Other institutional6.46%
Mutual fund holders4.48%
Individual stakeholders--

Top Executives

Marc OczachowskiChief Executive Officer
Francois DietschChief Financial Officer
Blandine ConfortHead-Investor Relations & Legal Affairs